Publications, Pharmaceutical

How pMDIs are transforming Asthma and COPD treatments

Pressurized metered dose inhalers have been used to treat asthma and COPD for over 60 years. However, the technologies within the pMDI container closure system and the drug and its formulation are very different and continue to evolve to meet patient needs, contain costs, and address changes in regulatory and environmental laws.  The immediate challenge to the Pharmaceutical industry however, is how to develop more sustainable pMDIs while at the same time, maintain patients adherence and compliance to their familiar treatment, lower the GWP of inhalers and to lower the overall carbon footprint of treatment.

This interview reviews some of these challenges and development timelines for new sustainable pMDIs as well as the discussion around dose counters in all future pressurized metered dose inhalers.

Download the publication on Dose and Delivery: How pMDIs are Transforming Asthma and COPD
Author(s): Chris Baron
12 Jul 2022

This article was taken from Pharmafile Summer 2022, page 22. Samedan Ltd

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More About pulmonary drug delivery expertise

This Might Also Be of Interest

3 Jul 2023

Orally Inhaled Drug products; Bioequivalence Models

Publications, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights

Read More
10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
24 Apr 2023

Navigating pMDI Reformulation 2.0

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
19 Apr 2023

Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 4 5 6 … 19

How Can We Help?

Back To Top